This announcement is a separate document:
百诚医药：上海信公轶禾企业管理咨询有限公司关于杭州百诚医药科技股份有限公司2022年限制性股票激励计划首次及预留授予部分第一个归属期归属相关事项之独立财务顾问报告
Baicheng Pharmaceutical: Shanghai Xingong Yihe Enterprise Management Consulting Co., Ltd.\'s independent financial advisory report on matters relating to the first restricted stock incentive plan of Hangzhou Baicheng Pharmaceutical Technology Co., Ltd. and
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.